Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of "Buy" by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $37.17.

A number of analysts have commented on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the transaction, the chief financial officer now owns 23,382 shares in the company, valued at approximately $540,124.20. The trade was a 27.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This represents a 25.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,766 shares of company stock worth $2,011,735 in the last ninety days. 54.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Braidwell LP lifted its stake in Kiniksa Pharmaceuticals by 19.3% during the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after buying an additional 557,934 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after acquiring an additional 54,361 shares during the period. Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals by 50.9% in the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after acquiring an additional 263,146 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after purchasing an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC grew its position in Kiniksa Pharmaceuticals by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock worth $15,141,000 after purchasing an additional 10,209 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Trading Up 3.5 %

KNSA traded up $0.66 during trading hours on Monday, hitting $19.31. The company's stock had a trading volume of 692,369 shares, compared to its average volume of 458,499. The company has a 50-day simple moving average of $20.97 and a 200 day simple moving average of $21.62. The firm has a market capitalization of $1.40 billion, a PE ratio of -137.92 and a beta of 0.31. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue for the quarter was up 46.9% on a year-over-year basis. During the same period last year, the business posted $0.35 earnings per share. Research analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.